VoterlyH.R. 7667: Food and Drug Amendments of 2022
117th Congress · Sponsored from California · In progress
What this bill does
Food and Drug Amendments of 2022 This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars. The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials. In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.
Key facts
- Status In progress
- Introduced 2022-05-06
- Policy area Health
- Cosponsors 3
- Latest action Received in the Senate.
Sponsor
Who funds the sponsor?
Rep. Eshoo, Anna G. [D-CA-18] introduced H.R. 7667. On Voterly you can see their top campaign donors from public Federal Election Commission records — individuals, PACs, and industry groups (follow the money) — and compare that with how they vote.
See Rep. Eshoo, Anna G. [D-CA-18]'s donors & voting record →
Campaign donations show who helps fund the sponsor's election; they are not the same as who drafted or lobbied for the bill text. Lobbying disclosures are separate public records.
Take a position & compare alignment
Agree or disagree with H.R. 7667? Go to the homepage to record your view and compare your stance with how your representatives vote. See Rep. Eshoo, Anna G. [D-CA-18]'s profile to vote on their bills and check your alignment % with the sponsor.
Read the official text on Congress.gov →
Frequently asked questions
What does H.R. 7667 do?
Food and Drug Amendments of 2022 This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs …
Who sponsored H.R. 7667?
Rep. Eshoo, Anna G. [D-CA-18] (D) of California is the lead sponsor.
How do I find out who funds or lobbies for H.R. 7667?
Campaign-finance records (Federal Election Commission) show who funds the bill's sponsor. Separately, federal lobbying disclosures filed under the Lobbying Disclosure Act list the companies and lobbyists who reported lobbying on specific bills. Voterly links the sponsor's donors; lobbying records are public at the U.S. Senate and House lobbying databases.
Is H.R. 7667 now law?
Not yet. The current status is "In progress." See the latest action above for details.